Paper Details

  1. Home
  2. Paper Details

Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.

Author: ChanNoel C, WeitzJeffrey I

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rivaroxaban, a blood thinner, has been shown to be more effective than aspirin in preventing blood clots in patients with venous thromboembolism.
Paper Details　
Original Abstract of the Article :
Many patients with venous thromboembolism (VTE) are at risk of recurrence if anticoagulant therapy is stopped. Whereas 3 months of anticoagulation treatment is sufficient for patients with VTE provoked by major surgery or trauma, in many cases a longer course is needed. Extended therapy with vitamin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0039-1679906

データ提供：米国国立医学図書館（NLM）

Venous Thromboembolism: A Desert of Blood Clots

Venous thromboembolism (VTE), a condition characterized by blood clots in the veins, is a serious health threat. It's like a hidden desert oasis that suddenly turns treacherous, harboring dangerous blood clots that can disrupt blood flow and lead to complications. This article discusses the long-term management of VTE, focusing on the challenges and potential solutions for preventing recurrence of these dangerous clots.

Navigating the Desert of Anticoagulation: Finding the Right Path

The authors discuss the use of various anticoagulants, medications that prevent blood clots, for long-term VTE management. They highlight the challenges associated with traditional anticoagulants, including the need for frequent monitoring and the risk of bleeding. They also explore the potential benefits of newer non-VKA oral anticoagulants (NOACs) which offer a more convenient and potentially safer approach. It's like finding a smoother and more reliable path through the desert, reducing the risk of unexpected dangers.

A Breakthrough in the Desert: The EINSTEIN CHOICE Trial

The article emphasizes the significance of the EINSTEIN CHOICE trial, which demonstrated the effectiveness of rivaroxaban, a NOAC, in preventing recurrent VTE compared to aspirin, a medication often used for its perceived lower risk of bleeding. This trial offers a promising oasis in the desert of VTE management, providing a more effective and potentially safer option for patients at risk of recurrence.

Dr. Camel's Conclusion

This article underscores the importance of continued research and innovation in the field of VTE management. The desert of blood clots presents a constant threat, but with the development of new and effective treatments, we are making significant strides in preventing recurrence and improving the lives of those affected by this serious condition.

Date :
  1. Date Completed 2020-01-09
  2. Date Revised 2020-01-09
Further Info :

Pubmed ID

30808045

DOI: Digital Object Identifier

10.1055/s-0039-1679906

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.